<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02782312</url>
  </required_header>
  <id_info>
    <org_study_id>20110505</org_study_id>
    <nct_id>NCT02782312</nct_id>
  </id_info>
  <brief_title>Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis</brief_title>
  <official_title>Salmeterol-Fluticasone Combined Inhaled Therapy for Non-cystic Fibrosis Bronchiectasis With Airway Limitation: a Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Pulmonary Hospital, Shanghai, China</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Pulmonary Hospital, Shanghai, China</source>
  <brief_summary>
    <textblock>
      The objective of this study is to assess the efficacy and safety of Salmeterol-Fluticasone
      （ICS and LABA）combined inhaled therapy for non-cystic fibrosis（non-CF）bronchiectasis patients
      with chronic airflow obstruction. Moreover, subgroup analysis is performed to explore which
      populations of bronchiectasis patients this treatment is suitable for.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Inhaled ICS and LABA have proved obvious benefit for asthma or chronic obstructive pulmonary
      disease (COPD) patients. However, there is presently no clear evidence on the effect of ICS
      and LABA combined inhaled therapy for non-CF bronchiectasis patients.

      This study is designed as a prospective, randomized,control trial. Patients are divided into
      two groups, one group inhaled with ICS and LABA (Seretide), another group received routine
      therapy (oxygen uptake, phlegm dissipation, hemostasis postural drainage and naturopathy).The
      course of treatment is 12 months. All patients underwent reviews at baseline entry to the
      study and at months 6 and 12 of treatment.

      The quality of life (QOL) scores：St George's dyspnea score (SGRQ score）, modified british
      medical reserach council（mMRC score) and COPD assessment test (CAT score); lung function
      test: forced expiratory volume in one second (FEV1）,FEV1% predicted, the ratio of forced
      expiratory volume in one second and forced vital capacity (FEV1/FVC%); short-acting
      β2-adrenergic agonist（SABA）use and the incidence of adverse event were monitored throughout
      the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">June 2013</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>CAT score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>mMRC score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Quality of life</measure>
    <time_frame>12 months</time_frame>
    <description>SGRQ score</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>pulmonary function text</measure>
    <time_frame>12 months</time_frame>
    <description>FEV1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary function text</measure>
    <time_frame>12 months</time_frame>
    <description>FEV1% predicted</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>pulmonary function text</measure>
    <time_frame>12 months</time_frame>
    <description>FEV1/FVC</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>short-acting β2-adrenergic agonist (SABA) used</measure>
    <time_frame>12 months</time_frame>
    <description>Number of SABA needed per patient every week</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exacerbations</measure>
    <time_frame>12 months</time_frame>
    <description>The times of acute exacerbation during the trial.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>sputum microorganism culture</measure>
    <time_frame>12 months</time_frame>
    <description>Number of microorganism isolates along the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>12 months</time_frame>
    <description>All of the adverse events occurred in the processing of the trial,especially adverse events associated with inhaled corticosteroids</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Bronchiectasis</condition>
  <arm_group>
    <arm_group_label>ICS+LABA Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Seretide 250，inhalation，twice daily，one year</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>routine therapy for one year</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ICS+LABA</intervention_name>
    <description>Seretide is inhaled for one year</description>
    <arm_group_label>ICS+LABA Group</arm_group_label>
    <other_name>Seretide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>routine therapy</intervention_name>
    <description>routine therapy for one year</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  stable bronchiectasis; have the ability to complete the pulmonary function tests;
             FEV1/FVC&lt;70%; ≥2 exacerbations within the past year

        Exclusion Criteria:

          -  a cigarette smoking history more than 10 pack-years;cystic fibrosis or traction
             bronchiectasis due to various pulmonary fibrosis; an active pulmonary mycobacterial
             infection; fungal infection; active sarcoidosis; active allergic bronchopulmonary
             aspergillosis (ABPA); asthma as defined by the Global Initiative for Asthma (GINA);
             patients with severe cardiopulmonary dysfunction; with impaired hepatic or kidney
             function; with hypogammaglobulinemia or other autoimmune diseases; pregnant or
             breast-feeding women; or patients with a known intolerance for ICS or LABAs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jin-Fu Xu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Pulmonary Hospital , Tongji University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Pulmonary Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <results_reference>
    <citation>Martínez-García MÁ, Soler-Cataluña JJ, Catalán-Serra P, Román-Sánchez P, Tordera MP. Clinical efficacy and safety of budesonide-formoterol in non-cystic fibrosis bronchiectasis. Chest. 2012 Feb;141(2):461-468. doi: 10.1378/chest.11-0180. Epub 2011 Jul 21.</citation>
    <PMID>21778259</PMID>
  </results_reference>
  <results_reference>
    <citation>Tsang KW, Tan KC, Ho PL, Ooi GC, Ho JC, Mak J, Tipoe GL, Ko C, Yan C, Lam WK, Chan-Yeung M. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax. 2005 Mar;60(3):239-43.</citation>
    <PMID>15741443</PMID>
  </results_reference>
  <results_reference>
    <citation>Goyal V, Chang AB. Combination inhaled corticosteroids and long-acting beta2-agonists for children and adults with bronchiectasis. Cochrane Database Syst Rev. 2014 Jun 10;(6):CD010327. doi: 10.1002/14651858.CD010327.pub2. Review.</citation>
    <PMID>24913725</PMID>
  </results_reference>
  <verification_date>May 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 17, 2016</study_first_submitted>
  <study_first_submitted_qc>May 24, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2016</study_first_posted>
  <last_update_submitted>May 25, 2016</last_update_submitted>
  <last_update_submitted_qc>May 25, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Pulmonary Hospital, Shanghai, China</investigator_affiliation>
    <investigator_full_name>Jin-Fu Xu</investigator_full_name>
    <investigator_title>Director of respiratory department</investigator_title>
  </responsible_party>
  <keyword>Bronchiectasis</keyword>
  <keyword>ICS+LABA</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchiectasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluticasone</mesh_term>
    <mesh_term>Salmeterol Xinafoate</mesh_term>
    <mesh_term>Fluticasone Propionate, Salmeterol Xinafoate Drug Combination</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

